BMEA Stock — Biomea Fusion Inc.: Cash, EV, Pipeline

Share price

$1.83

Market cap

$132.6M

Cash

$34.8M

Enterprise value

$97.8M

Balance sheet

Cash	$34.8M
Debt	$0.0M
Net cash	$34.8M
Enterprise value	$97.8M
Basic shares	72.5M shares
Fully diluted shares	129.9M shares
Fully diluted market cap	$237.8M
Cash per share	$0.48

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BMEA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	icovamenib 100mg	Phase 2	Type 2 Diabetes	Q1 2027
Jul 13 - Aug 24	icovamenib 100 mg	Phase 2	Type 2 Diabetes	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Icovamenib

Phase 2 · Active Modality: oral covalent small molecule

Target menin

Indications

Type 2 diabetes (Phase 2)
Type 1 diabetes (Phase 2)
Obesity (Stage not disclosed)

Catalysts

— Q4 2026

Status note Lead program; oral covalent menin inhibitor. COVALENT-112 T1D topline reported Apr 2026; only the two T2D Phase 2 trials (COVALENT-211/212) listed as ongoing as of Jun 30, 2026. Oncology exploration explicitly discontinued; obesity impact under investigation (preclinical).

BMF-650

Phase 1 · Active Modality: oral small molecule

Target GLP-1 receptor

Indications

Obesity (Phase 1)

Catalysts

— Q3 2026

Status note Next-generation oral GLP-1 receptor agonist; IND cleared Sep 2025; Phase I GLP-131 trial ongoing.

BMF-500

Stage not disclosed · Active Modality: covalent small molecule

Target FLT3

Indications

Oncology (indication not stated) (Stage not disclosed)

Status note Covalent FLT3 inhibitor. Internal oncology work deprioritized (icovamenib oncology studies discontinued); company plans to explore partnerships to advance BMF-500 while concentrating internal resources on metabolic disorders.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	icovamenib 100mg
Lead indication	Type 2 Diabetes
Lead phase	Phase 2
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07502495	Phase 2	Active, not recruiting	Sponsor	BMEA	—	Type 2 Diabetes	Q1 2027
NCT07502508	Phase 2	Recruiting	Sponsor	BMEA	—	Type 2 Diabetes	—
NCT05918692	Phase 1	Active, not recruiting	Sponsor	BMEA	—	Acute Myeloid Leukemia	—
NCT07223216	Phase 1	Active, not recruiting	Sponsor	BMEA	—	Obesity	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Biomea Fusion Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	43,420	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

BMEA — Biomea Fusion Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders